24/7 Market News Snapshot 08 January, 2025 – AngioDynamics, Inc. (NASDAQ:ANGO)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (NASDAQ:ANGO) are discussed in this article.
AngioDynamics, Inc. has entered a dynamic phase marked by significant market activity and impressive financial growth. Following a remarkable increase in its stock price, which climbed over 28% this week after opening at $11.76 and reaching $12.04, a growing confidence among investors is evident. This surge comes on the heels of the company’s robust second quarter financial results for the fiscal year 2025, concluding on November 30, 2024, where it achieved pro forma net sales of $73.0 million, reflecting a year-over-year increase of 9.2%.

This growth is particularly driven by the company’s Med Tech segment, which saw a notable 25% rise to $31.5 million, supported by strong demand for key product lines such as the Auryon peripheral atherectomy platform and the NanoKnife irreversible electroporation system. While there was a minor dip in Med Device net sales, total net sales across the U.S. reached $62.7 million, a 12.3% increase from the previous year.

AngioDynamics reported a GAAP gross margin of 54.8% and an adjusted EBITDA of $3.1 million, illustrating its commitment to operational efficiency and profitability. Recent developments, including the awarding of CPT Category I Codes and FDA 510(k) clearance for prostate tissue ablation using the NanoKnife System, bolster the company’s potential for sustained growth in the oncology sector.

In light of these developments, AngioDynamics has adjusted its fiscal year 2025 guidance, projecting net sales between $282 million and $288 million. This forecast reflects confidence in the company’s strategic initiatives aimed at enhancing market access for its innovative technologies. CEO Jim Clemmer acknowledged the significance of these advancements, emphasizing the company’s dedication to improving patient care while transforming the medical landscape for conditions such as peripheral vascular disease and cancer.

Related news for (ANGO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.